Edwards Lifesciences (NYSE:EW) Sets New 12-Month High Following Analyst Upgrade

Edwards Lifesciences Corporation (NYSE:EW) reached a new 52-week high on Tuesday after BTIG Research raised their price target on the stock from $100.00 to $110.00. BTIG Research currently has a buy rating on the stock. Edwards Lifesciences traded as high as $92.88 and last traded at $91.3310, with a volume of 3606234 shares. The stock had previously closed at $90.78.

A number of other equities analysts have also recently commented on the company. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research note on Wednesday, April 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.39.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 58,977 shares of company stock valued at $4,921,803 over the last quarter. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP acquired a new position in Edwards Lifesciences during the 3rd quarter worth about $238,688,000. Marshall Wace LLP grew its position in shares of Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after buying an additional 2,359,128 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Edwards Lifesciences by 132.4% in the 1st quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock valued at $310,984,000 after buying an additional 2,212,208 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.7%

The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a market cap of $52.95 billion, a price-to-earnings ratio of 48.91, a PEG ratio of 2.27 and a beta of 0.85. The firm has a 50 day moving average price of $85.06 and a two-hundred day moving average price of $83.41.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the business posted $0.64 earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.